Paul Whaley: Is it really sensible to wait and see?

Comment

Thursday 01 April 2010 00:00 BST
Comments

Your support helps us to tell the story

This election is still a dead heat, according to most polls. In a fight with such wafer-thin margins, we need reporters on the ground talking to the people Trump and Harris are courting. Your support allows us to keep sending journalists to the story.

The Independent is trusted by 27 million Americans from across the entire political spectrum every month. Unlike many other quality news outlets, we choose not to lock you out of our reporting and analysis with paywalls. But quality journalism must still be paid for.

Help us keep bring these critical stories to light. Your support makes all the difference.

In February this year, the US Maryland DC Society of Clinical Oncologists issued the most unequivocal statement yet about bisphenol A, saying: "Make no mistake about it: the research is clear and reproducible in multiple studies. This product is dangerous."

Which is a stark statement to make about a substance widely found in food packaging, linings of tins and drinks, dental sealant and polycarbonate plastics and which biomonitoring studies have found is present in 92 per cent of adults.

Health problems have been discovered in the overwhelming majority of published studies. Animal research has connected bisphenol A (BPA) exposure to a range of health problems including metabolic disorders and obesity, male fertility problems, asthma and intestinal inflammation. Recent human epidemiological research has implicated BPA exposure in elevated risk of heart disease.

Research focusing on the effects of prenatal exposure strongly suggests that exposure to BPA in the womb pre-programmes adult health problems. Nor are these effects being observed at high doses, but at the levels at which people have BPA in their blood – levels which are much lower than that permitted by regulators.

Human data is undoubtedly lacking. There are technical reasons for this: with BPA, the simple ubiquity of exposure presents a serious challenge. Where researchers can easily compare groups of smokers to groups of non-smokers to determine the effects of smoking, with BPA it is very hard to isolate people who are exposed from people who are not. The 20-, 30- or 40-year delay between exposure and health consequence also makes it difficult to identify health effects.

There is also the issue of ethical constraints on research: we can't test potentially harmful chemicals on pregnant women to find out about health effects on their children, making researchers dependent on animal studies.

But, given that almost everyone has BPA in their bodies, and that the children of pregnant women are exposed even before birth to a chemical with demonstrated potential to pre-programme animals for adult illness, the question to ask must be: given the evidence we already have, is it really sensible to wait and see what effects BPA has in people before restricting use of the chemical?

Paul Whaley is communications manager for the Cancer Prevention and Education Society

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in